Human leukocyte antigen–G is upregulated in heart failure patients: A potential novel biomarker

Abstract Immune activation and inflammation play critical roles in the development of heart failure (HF). Human leukocyte antigen–G (HLA-G) is a nonclassical, major histocompatibility complex class I (MHC–I) protein, upregulated in the context of transplantation, malignancy, and inflammation, and ha...

Full description

Saved in:
Bibliographic Details
Published in:Human immunology 2011-11, Vol.72 (11), p.1064-1067
Main Authors: Almasood, Ali, Sheshgiri, Rohit, Joseph, Jemy M, Rao, Vivek, Kamali, Mahsa, Tumiati, Laura, Ross, Heather J, Delgado, Diego H
Format: Article
Language:English
Subjects:
Adult
Aged
Allergy and Immunology
Biomarker
Biomarkers - blood
Cytokines - blood
Disease Progression
Female
Heart failure
Heart Failure - diagnosis
Heart Failure - immunology
Heart Failure - pathology
Heart Failure - physiopathology
Heart Function Tests
HLA-G Antigens - biosynthesis
HLA-G Antigens - blood
HLA-G Antigens - genetics
HLA-G Antigens - immunology
Human leukocyte antigen-G
Humans
Male
Middle Aged
Pilot Projects
Sensitivity and Specificity
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Immune activation and inflammation play critical roles in the development of heart failure (HF). Human leukocyte antigen–G (HLA-G) is a nonclassical, major histocompatibility complex class I (MHC–I) protein, upregulated in the context of transplantation, malignancy, and inflammation, and has been correlated with various clinical outcomes. We sought to evaluate the utility of plasma HLA-G in identifying patients with HF. We conducted a single-center, cross-sectional pilot study involving 82 patients diagnosed with HF and 10 healthy controls. Concentrations of circulating HLA-G and inflammatory markers were detected with specific enzyme-linked immunosorbent assay kits and quantified according to purified protein standards. The mean age of the patients was 49.1 ± 12.0 years and 62.2% were male. The median and interquartile range of HLA-G levels (U/ml) were significantly higher ( p < 0.001) in HF patients (63, 36–98) compared with controls (28, 22–40). Moreover, HLA-G levels that were similarly ( p = 0.766) upregulated across all New York Heart Association functional classes. There was no significant correlation between serum HLA-G and other biomarkers. In conclusion, HLA-G is upregulated in patients diagnosed with HF. Its marked elevation even in New York Heart Association class I patients might indicate that serum HLA-G is a more sensitive marker than other classical HF biomarkers.
ISSN:0198-8859
1879-1166
DOI:10.1016/j.humimm.2011.08.016